Therapeutic chaperone effect of N-Octyl 4-Epi-β-valienamine on murine GM1-gangliosidosis

Add time:08/18/2019    Source:sciencedirect.com

Therapeutic chaperone effect of a valienamine derivative N-octyl 4-epi-β-valienamine (NOEV) was studied in GM1-gangliosidosis model mice. Phamacokinetic analysis revealed rapid intestinal absorption and renal excretion after oral administration. Intracellular accumulation was not observed after continuous treatment. NOEV was delivered to the central nervous system through the blood–brain barrier to induce high expression of the apparently deficient β-galactosidase activity. NOEV treatment starting at the early stage of disease resulted in remarkable arrest of neurological progression within a few months. Survival time was significantly prolonged. This result suggests that NOEV chaperone therapy will be clinically effective for prevention of neuronal damage if started early in life hopefully also in human patients with GM1-gangliosidosis.

We also recommend Trading Suppliers and Manufacturers of CHOLESTEROL N-OCTYL CARBONATE (cas 15455-82-0). Pls Click Website Link as below: cas 15455-82-0 suppliers

Prev:Research paperSynthesis and evaluation of vitamin D receptor-mediated activities of cholesterol and vitamin D metabolites
Next:Diphenylpolyene-cholesterol conjugates as fluorescent probes for microheterogeneous media)